Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

AJ Cooper, LV Sequist, JJ Lin - Nature Reviews Clinical Oncology, 2022 - nature.com
The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
被引用次数：192 相关文章

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

AJ Cooper, LV Sequist, JJ Lin - Nature reviews. Clinical …, 2022 - pubmed.ncbi.nlm.nih.gov
The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

AJ Cooper, LV Sequist, JJ Lin - Nature reviews. Clinical Oncology, 2022 - europepmc.org
The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
[HTML] nih.gov

[HTML][HTML] Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

AJ Cooper, LV Sequist, JJ Lin - Nature reviews. Clinical oncology, 2022 - ncbi.nlm.nih.gov
The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …